Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 144

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 144
---
 our future earnings, if any, to
fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source
of gain, if any, for any stockholders for the foreseeable future

 25 

    ITEM 1B.
    UNRESOLVED STAFF COMMENTS

Not applicable.

    ITEM 1C.
    CYBERSECURITY

Risk Management and Strategy

We recognize the importance of assessing, identifying,
and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks
include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees or customers and violation
of data privacy or security laws. While do not presently have any general processes for assessing, identifying, and managing material
risks from cybersecurity threats due to our limited financial resources, we do oversee certain third-party service providers and we plan
to institute broader cybersecurity measures at such time we are able to raise sufficient capital.

Oversee Third-party Risk

Because we are aware of the risks associated with
third-party service providers, we oversee and manage these risks by monitoring these third-party service providers and reviewing SOC reports
of these providers and implementing complementary controls, if necessary. This approach is designed to mitigate risks related to data
breaches or other security incidents originating from third parties.

Risks from Cybersecurity Threats

We have not encountered cybersecurity challenges that
have materially impaired our operations or financial standing.

    ITEM 2.
    PROPERTIES

The Company has no properties at December 31, 2024,
and at the period covered by this Report, has no agreements to acquire any properties. The Company currently uses the home offices of
management at no cost to the Company. The Company expects this arrangement to continue until the Company can raise sufficient capital
and potentially license or acquire new technologies.

    ITEM 3.
    LEGAL PROCEEDINGS

Information pertaining to legal proceedings is provided
in Note 10, Commitments and Contingencies, to the accompanying audited consolidated financial statements and is incorporated by reference
herein.

    ITEM 4.
    MINE SAFETY DISCLOSURES

Not applicable.

 26 

PART II

    ITEM 5.
    MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market Information

Our common